Neimeth Outshines Pharmaceutical Peers with 26% Revenue Growth in H1 2026

Neimeth International Pharmaceuticals Plc has emerged as the fastest-growing listed pharmaceutical company by revenue in the first half of 2026. It achieved a significant 26% year-on-year increase in sales, demonstrating resilience in a challenging economic climate marked by high borrowing costs, inflation, and foreign exchange volatility.

An analysis of financial statements for Neimeth, Fidson Healthcare Plc, and May & Baker Nigeria Plc revealed that while Fidson maintained its lead in revenue and profitability, Neimeth delivered the strongest top-line growth. This performance reflects enhanced market penetration and consistent demand for its pharmaceutical products. Neimeth's revenue climbed to N3.66 billion for the six months ending June 30, 2026, up from N2.91 billion in the same period of 2025.

Industry analysts attribute Neimeth's faster revenue growth to successful market expansion, strong product acceptance, and effective commercial strategies in a competitive market. The company also sustained profitability, with profit after tax increasing to N207.66 million from N203.76 million in the first half of 2025. This resilience was achieved despite elevated financing costs.

Neimeth's financial health was further supported by a healthy gross margin, with gross profit rising 15% to N1.82 billion, nearly half of its total revenue. This indicates an ability to preserve value amidst rising costs for imported raw materials, inflation, and logistics. Operational efficiency also improved, with administrative expenses declining approximately 6% year-on-year, showcasing effective cost controls as the business expanded.

Shareholders' equity grew to N2.84 billion by the end of June 2026, up from N2.63 billion in December 2025, driven by retained earnings. While Neimeth remains the smallest among its peers in revenue, assets, and earnings, Fidson Healthcare reported N74.48 billion in revenue and May & Baker posted N19.26 billion, its performance highlights its growing market strength and operational capabilities.